United States - English - NLM (National Library of Medicine)

baradaina, llc - dapiprazole hydrochloride (unii: ds9ujn1i0x) (dapiprazole - unii:5rnz8gjo7k) - dapiprazole hydrochloride ophthalmic solution is indicated in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents. dapiprazole hydrochloride ophthalmic solution is not indicated for the reduction of intraocular pressure or in the treatment of open angle glaucoma. miotics are contraindicated where constriction is undesirable; such as acute iritis, and in those subjects showing hypersensitivity to any component of this preparation.

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate injection, usp is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis - e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. but since an appreciable time int

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 20 mg - citalopram tablets, usp are indicated for the treatment of depression. the efficacy of citalopram in the treatment of depression was established in 4 to 6 week; controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram tablets, usp in hospitalized depressed patients has not been adequately studied. the efficacy

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - alfuzosin hydrochloride (unii: 75046a1xtn) (alfuzosin - unii:90347ytw5f) - alfuzosin hydrochloride 10 mg - alfuzosin hydrochloride is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. alfuzosin hydrochloride is not indicated for the treatment of hypertension. alfuzosin hydrochloride is not indicated for use in the pediatric population. alfuzosin hydrochloride is contraindicated for use: - in patients with moderate or severe hepatic impairment (childs-pugh categories b and c), since alfuzosin blood levels are increased in these patients [see use in specific populations (8.7) and clinical pharmacology (12.3)] . - with potent cyp3a4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see drug interactions (7.1) and clinical  pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of alfuzosin hydrochloride tablets [see adverse reactions (6.2)] . pregnancy category b. alfuzosin hydrochloride is not indicated for use in women, and there are no s

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - amlodipine 10 mg - amlodipine besylate tablets, usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. chronic stable angina amlodipine besylate tablets, usp are indicated for the symptomatic treatment of chronic stable angina. amlodipine besylate tablets, usp may be used alone or in combination with other antianginal agents. vasospastic angina (prinzmetal’s or variant angina) amlodipine besylate tablets are indicated for the treatment of confirmed or suspected vasospastic angina. amlodipine besylate tablets, usp may be used as monotherapy or in combination with other antianginal agents. angiographically documented cad in patients with recently documented cad by angiography and without heart failure or an ejection fraction <40%, amlodipine besylate tablets, usp are indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. amlodipine besylate tablets are contraindicated in patients wit

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - amlodipine 5 mg - amlodipine besylate tablets, usp are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. chronic stable angina amlodipine besylate tablets, usp are indicated for the symptomatic treatment of chronic stable angina. amlodipine besylate tablets, usp may be used alone or in combination with other antianginal agents. vasospastic angina (prinzmetal’s or variant angina) amlodipine besylate tablets are indicated for the treatment of confirmed or suspected vasospastic angina. amlodipine besylate tablets, usp may be used as monotherapy or in combination with other antianginal agents. angiographically documented cad in patients with recently documented cad by angiography and without heart failure or an ejection fraction <40%, amlodipine besylate tablets, usp are indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. amlodipine besylate tablets are contraindicated in patients wit

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram tablets, usp are indicated for the treatment of depression. the efficacy of citalopram in the treatment of depression was established in 4 to 6 week; controlled trials of outpatients whose diagnosis corresponded most closely to the dsm-iii and dsm-iii-r category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the antidepressant action of citalopram tablets, usp in hospitalized depressed patients has not been adequately studied. the efficacy

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - topiramate (unii: 0h73wjj391) (topiramate - unii:0h73wjj391) - topiramate tablets are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. topiramate tablets are indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age and older. topiramate tablets are indicated for the preventive treatment of migraine in patients 12 years of age and older. none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to topiramate during pregnancy. patients should be encouraged to enroll in the north american antiepileptic drug (naaed) pregnancy registry if they become pregnant. this registry is collecting information about the safety of antiepileptic drugs during pregnancy. to enroll, patients can call the toll-free number 1-888-233-2334. information about the north american drug pregnancy

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - escitalopram oxalate (unii: 5u85dbw7lo) (escitalopram - unii:4o4s742any) - escitalopram tablets, usp are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [see clinical studies (14.1)]. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. escitalopram is indicated for the acute treatment of generalized anxiety disorder (gad) in adults [see clinical studies (14.2)]. generalized anxiety disorder (dsm-iv) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least s

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adcockcc -